Giulia Nemola, Anita Russi, Gianmarco Cozzani, Giulio Leo, Laura Vetrugno, Francesco Maria Sparasci, Antonio Lm Parlati, Paolo Della Bella, Matteo Montorfano, Moreno Tresoldi, Anna Salerno, Michela Cera, Paolo Mattiello, Giancarlo Comi, Francesco Maisano, Alberto Zangrillo, Carlo Gaspardone, Francesco Melillo, Alberto Margonato, Cosmo Godino
Direct oral anticoagulants (DOACs) represent the cornerstone therapy for cardioembolic events prevention in patients with nonvalvular atrial fibrillation (NVAF). In practice, the choice of one DOAC over another is guided by the decision-making process of the physician, which considers specific patient and drug characteristics. This study aimed to evaluate the clinical features and long-term outcomes of a real-world population treated with DOACs, where the use of the 4 different DOACs is quite equal. We conducted a retrospective observational, single-center, multidisciplinary study enrolling consecutive NVAF patients treated with one of the 4 DOACs...
November 1, 2023: American Journal of Cardiology